Non-Hodgkin lymphoma (NHL) treatment in Istanbul, Turkey
Non-Hodgkin lymphoma is not one disease but a large family — from indolent, slow-growing types like follicular lymphoma to aggressive ones like diffuse large B-cell lymphoma (DLBCL) — and the exact subtype decides everything. B-cell NHL is defined by antibody-based therapy: immunochemotherapy that combines the anti-CD20 antibody rituximab with chemotherapy, such as R-CHOP for DLBCL. Some indolent lymphomas are simply watched; relapsed aggressive disease may call for CAR T-cell therapy or a transplant. Istanbul hospitals offer this full pathway, often at JCI-accredited, state-authorized centers. Every price we show is an illustrative placeholder until verified partner-hospital quotes exist — and you pay the hospital directly, never us. Start with a free 72-hour review of your reports before you decide anything.
Structure of a lymph node — the afferent and efferent lymphatic vessels, capsule, sinus and nodules, the tissue involved in lymphomas.
SEER Training Modules, U.S. National Cancer Institute — public domain (opens in a new tab) ↗What non-Hodgkin lymphoma is
The U.S. National Cancer Institute describes adult non-Hodgkin lymphoma as a large, diverse group of cancers that form in the lymphatic system, the network of lymph nodes and tissue that is part of the immune system. What makes NHL distinct is its range: it spans indolent lymphomas that grow slowly, such as follicular lymphoma, and aggressive lymphomas that grow quickly, such as diffuse large B-cell lymphoma (DLBCL). Most are B-cell lymphomas, though some arise from T-cells, and the subtype dictates the whole approach.
Diagnosis usually involves a biopsy of an enlarged lymph node, and the extent of disease is worked out with CT or PET imaging and often a bone marrow examination. Crucially, molecular and immunophenotype testing defines the exact subtype — whether it is B-cell or T-cell, indolent or aggressive — and that classification, more than the word “lymphoma” alone, drives treatment. Browse the wider cancer types hub for related diagnoses.
Treatment options
The approaches the NCI lists for non-Hodgkin lymphoma, and an honest note on each:
- Immunochemotherapy. The mainstay for B-cell NHL — the anti-CD20 monoclonal antibody rituximab combined with chemotherapy, for example R-CHOP for diffuse large B-cell lymphoma. The antibody and chemotherapy work together; cost scales with the number of cycles.
- Active surveillance. For some indolent, asymptomatic lymphomas such as follicular lymphoma, the NCI describes watchful waiting — monitoring closely and starting treatment only when the disease progresses. Doing less, at the right time, is a legitimate plan, not a lack of one.
- CAR T-cell therapy & bispecific antibodies. For relapsed or refractory aggressive B-cell NHL, CAR T-cell therapy re-engineers your own immune cells to attack the lymphoma, and bispecific antibodies are another option. These are for disease that has returned or resisted first-line treatment, not usually a first step.
- Radiation & stem cell transplant. Radiation therapy is used for localized disease, and for selected relapse an autologous stem cell transplant uses your own stored cells to allow higher-dose treatment. Which applies is decided by your subtype and stage, not a template.
Some subtypes also respond to targeted therapy. See how these modalities work in general on the treatments & technology hub.
What it costs
There is no single non-Hodgkin lymphoma price, because the cost is driven by the subtype, the regimen, the number of immunochemotherapy cycles, whether radiation is used, and whether advanced options such as CAR T-cell therapy or stem cell transplant are involved — those can dominate the total, while an indolent lymphoma on active surveillance may need no treatment at all for a time. Every figure OncologyIstanbul™ publishes today is an illustrative placeholder pending verified partner-hospital quotes, and each is itemized so you can hold a real quote up against it line by line. See the Turkey Oncology Price Index or the full cancer treatment cost in Turkey breakdown.
The hospital, verified
We don’t show a wall of smiling doctors or a “ranked” list — those are the easiest things to fabricate. Instead, you’re matched to one state-authorized Istanbul partner hospital whose hematology and medical oncology subspecialty fits your diagnosis, and you can verify its authorization against the Republic of Turkey Ministry of Health’s own records and its JCI accreditation in JCI’s public directory before you commit. Named specialist profiles appear only when a verified, consented physician is behind the name. See the full guide to cancer hospitals in Istanbul and how to check one yourself.
Where this fits
Non-Hodgkin lymphoma is one branch of the broader lymphoma treatment overview, which itself sits within the cancer treatment in Istanbul pillar. If you want your own reports read first, a free second opinion organizes and verifies your pathology, immunophenotype and imaging into a plain-language case file in your language before you decide whether to travel.
Related cancers
Check everything here — us included
Common questions
Can I get non-Hodgkin lymphoma treatment in Turkey?
Yes. Istanbul hospitals provide the full NHL pathway the U.S. National Cancer Institute describes — immunochemotherapy combining the anti-CD20 antibody rituximab with chemotherapy (for example R-CHOP for diffuse large B-cell lymphoma), active surveillance for some slow-growing lymphomas, radiation for localized disease, and, for relapsed or refractory aggressive B-cell NHL, CAR T-cell therapy, bispecific antibodies, or autologous stem cell transplant. Many centers hold JCI accreditation and Turkish Ministry of Health state authorization, both of which you can check yourself before committing. The honest first step is a free case review of your pathology and immunophenotype so the plan is understood before you travel.
Why does the exact subtype of NHL matter so much?
Because non-Hodgkin lymphoma is not one disease — the NCI describes a large, diverse group of lymphomas, and the subtype decides the entire plan. An aggressive lymphoma such as diffuse large B-cell lymphoma grows fast and is often treated intensively with the intent to cure, while an indolent lymphoma such as follicular lymphoma may grow so slowly that the recommended approach is active surveillance, or watchful waiting, with no immediate drugs. Molecular and immunophenotype testing establishes the exact subtype and whether it is B-cell or T-cell. This is general information, not a treatment recommendation.
What is R-CHOP, and when is it used?
R-CHOP is a standard immunochemotherapy regimen the NCI describes for many B-cell non-Hodgkin lymphomas, most notably diffuse large B-cell lymphoma. The R stands for rituximab, an anti-CD20 monoclonal antibody that targets a protein on the surface of B-cells, and CHOP is a combination of chemotherapy drugs given with it. Combining the antibody with chemotherapy — immunochemotherapy — is the mainstay for B-cell NHL because the two work together. The number of cycles and whether R-CHOP or a related regimen fits depends on the subtype and stage, which is exactly what tumour testing and a case review clarify.
When is CAR T-cell therapy used for NHL, and what does it cost?
Per the NCI, CAR T-cell therapy and bispecific antibodies are options for relapsed or refractory aggressive B-cell lymphoma — disease that has come back or not responded after standard immunochemotherapy — not usually a first treatment. There is no single price, because cost is driven by the subtype, the regimen, the number of chemotherapy cycles, and whether advanced options such as CAR T-cell therapy or stem cell transplant are involved, which can dominate the total. Every figure OncologyIstanbul™ publishes today is an illustrative placeholder pending verified partner-hospital quotes, itemized so you can check a real quote line by line. You pay the hospital directly, never us.
Start with a free 72-hour case review
Send your pathology and imaging. Get a verified case file in your language — free, confidential, no obligation.
This page is general information, not medical advice. Medical facts are grounded in the U.S. National Cancer Institute; prices shown are illustrative placeholders pending verified partner-hospital quotes, not offers. Every cancer case is individual; assessments are based on the reports you provide and do not replace in-person examination.